Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial by Andersson, Charlotte et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Research
Differential changes in serum uric acid concentrations in 
sibutramine promoted weight loss in diabetes: results from four 
weeks of the lead-in period of the SCOUT trial
Charlotte Andersson*1, Peter Weeke1, Bente Brendorp2, Lars Køber3, 
Emil L Fosbøl1,  A r y aMS h a r m a 4, Nick Finer5, Ian D Caterson6, 
Richard A Rode7, Philip T James8 and Christian Torp-Pedersen1
Address: 1Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark, 2Department of Cardiology, Glostrup University Hospital, 
Denmark, 3The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark, 4University of Alberta, Royal Alexandra Hospital, 
Edmonton, Alberta, Canada, 5Addenbrooke's Hospital, Institute for Metabolic Science, Cambridge, UK, 6Institute of Obesity Nutrition & Exercise, 
University of Sydney, NSW Australia, 7Abbott Laboratories, Abbott Park, Illinois, USA and 8London School of Hygiene and Tropical Medicine, 
London, UK
Email: Charlotte Andersson* - ca@heart.dk; Peter Weeke - pw@heart.dk; Bente Brendorp - bb@heart.dk; Lars Køber - lk@heart.dk; 
Emil L Fosbøl - elf@heart.dk; Arya M Sharma - sharma@obesitynetwork.ca; Nick Finer - n.finer@ucl.ac.uk; 
Ian D Caterson - icaterson@med.usyd.edu.au; Richard A Rode - Richard.A.Rode@abbott.com; Philip T James - jeanhjames@aol.com; 
Christian Torp-Pedersen - ctp@heart.dk
* Corresponding author    
Abstract
Background and aims: Elevated levels of serum uric acid are associated with an increased risk
of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle
plus sibutramine) in an overweight and obese cardiovascular high risk population was studied.
Methods and results: Data from a four week single-blind lead-in period of the Sibutramine
Cardiovascular OUTcomes (SCOUT) study were analyzed. 2584 patients (24%) had diabetes
mellitus (DM) only, 1748 (16%) had cardiovascular disease (CVD) only and 6397 (60%) had both
DM + CVD. Uric acid concentrations (mean ± standard deviation) at screening were significantly
higher among patients with CVD compared to patients without CVD (p < 0.0001): 369 ± 86 μmol/
L, 374 ± 98 μmol/L and 342 ± 87 μmol/L in CVD only, CVD+DM and DM only groups, respectively.
During treatment uric acid decreased significantly more in patients without DM (p < 0.0001): -15.0
μmol/L (95% confidence interval -17.7;-12.4), -4.6 μmol/L (-6.2;-3.0), and -6.6 μmol/L (-8.7;-4.5) in
CVD only, CVD+DM, and DM only groups, respectively. In patients who failed to lose weight,
sibutramine induced lower uric acid levels, but greater weight loss and diabetes were associated
with smaller falls in blood uric acid levels; decreasing fasting and urinary glucose concentrations in
diabetes were associated with increases in uric acid levels.
Conclusion: A four week daily intake of sibutramine and life style changes was associated with
significant reductions in mean uric acid levels. Changes in renal glucose load in diabetes seem to
counteract a potential uricosuric effect of sibutramine.
Trial Registration: The trial is registered at ClinicalTrial.gov number: NCT00234832.
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Introduction
Large epidemiological studies of populations at increased
risk of cardiovascular events (including those with diabe-
tes, hypertension and a history of cardiovascular disease)
show hyperuricaemia to powerfully predict cardiovascular
adverse events and mortality[1-3], even within the high
normal range of uric acid concentrations[4]. Hyperuricae-
mia may, however, simply reflect established cardiovascu-
lar risk factors, such as hypertension and renal
impairment and not act causally[5].
Elevated serum uric acid levels, obesity, insulin resistance
and type 2 diabetes mellitus frequently coexist[6,7] and
weight loss with sibutramine reduces uric acid levels[8].
Whether this also occurs in patients at increased risk for
cardiovascular adverse events and in diabetes mellitus is
unknown. Therefore, we examined the uric acid response
to short (four week) weight loss therapy with sibutramine
in the overweight or obese, cardiovascular high risk pop-
ulation enrolled in the Sibutramine Cardiovascular OUT-
comes (SCOUT) study.
Methods
SCOUT is an ongoing randomized, double-blind, pla-
cebo-controlled clinical study of cardiovascular outcome
in overweight or obese patients at increased risk for cardi-
ovascular adverse events. Patients aged 55 years or older,
with a body mass index (BMI) ≥ 27 kg/m2 and ≤ 45 kg/m2,
or a BMI ≥ 25 kg/m2 and <27 kg/m2 plus a waist circum-
ference ≥ 102 cm if male and ≥ 88 cm if female, were
included. A further requirement was either the presence of
cardiovascular disease (CVD) (defined as a history of cor-
onary artery disease, peripheral arterial occlusive disease
or stroke), or diagnosed type 2 diabetes mellitus (DM)
with at least one additional well defined risk factor (i.e.
hypertension, dyslipidaemia, current smoker or diabetic
nephropathy with evidence of microalbuminuria)[9]. Fif-
teen months after initial enrolment, inclusion criteria
were modified due to a lower than expected overall pri-
mary outcome event rate. Thereafter, recruited patients
were required to have both CVD and DM. All inclusion
and exclusion criteria are described elsewhere[9]. Impor-
tantly, patients with more severe heart failure (i.e., greater
than New York Heart Association (NYHA) class II; diagno-
sis was based on patient history and also requiring medi-
cal treatment) were excluded.
The present analyses deal with the first four weeks of the
6-week, single-blind, lead-in period of the SCOUT trial.
The single-blind period preceded randomization into the
main study, with all subjects receiving 10 mg sibutramine
daily together with advice on diet and physical exercise. At
the screening visit and every other week, a physical exam-
ination, including measurements of weight, height, blood
pressure and pulse, was performed. Data on haematology
and blood biochemistry were collected at the screening
visit and after four weeks of treatment. All blood samples
were taken fasting and analysed in a certified central labo-
ratory. Some of the patients had a second haematology or
blood biochemistry sample taken either in relation to the
screening visit or in relation to the four week visit. For the
present analysis, these secondary blood samples were
used only if values from the first measurement were miss-
ing. Uric acid concentration had a normal reference
defined as 150-450 μmol/L for women and 240-510
μmol/L for men. Creatinine clearance was calculated from
measured creatinine concentrations, using the Modifica-
tion of Diet in Renal Disease (MDRD) study equa-
tion[10].
All patients provided urinary samples that were semi-
quantitatively (i.e., by dip stick) analyzed for ketone bod-
ies, blood, proteins and glucose. For glucose, the dip stick
scale spanned from "negative", "trace", "1+", "2+" to "3+".
A one unit change of urinary glucose was defined as a
change of one step on the scale (e.g., from trace to 1+, or
from trace to negative).
The population was classified according to the presence of
diabetes mellitus, and/or cardiovascular disease, using the
inclusion diagnoses. Thirteen of 10,742 patients (0.12%)
could not be classified in any of these groups because of
missing data, and were therefore not included in the
present analysis. In analyses stratified by diabetes, the dia-
betes group included the patients originally grouped in
DM only group or in CVD+DM group. In analyses strati-
fied by weight change, patients who maintained or gained
weight were defined as one group and the other groups
were composed according to each percentage of weight
loss (i.e. lost >0-1%; lost >1-2%; lost >2-3%; lost >3-4%;
and lost > 4% of their initial weight, respectively; further
information and distribution of patients in the different
weight change groups are available elsewhere[11]).
Ethics
The study was performed in conformity with the Declara-
tion of Helsinki and was approved by all relevant ethical
committees. All patients gave their written, informed con-
sent before participating. The trial is registered at Clinical-
Trial.gov number: NCT00234832.
Statistics
Continuous variables were compared by t-test and analy-
sis of variance (ANOVA). Discrete variables were com-
pared with chi-square test. All tests were repeated with
non-parametric methods (rank sum test for continuous
variables and Mantel-Haenszel chi square for discrete var-
iables). Unless specified, results from the parametric mod-
els have been reported. General linear models were used
to examine the impact of different factors on the changeNutrition & Metabolism 2009, 6:42 http://www.nutritionandmetabolism.com/content/6/1/42
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in uric acid concentration. Irrespective of significance lev-
els, all variables with a possible influence on uric acid lev-
els were included in multivariable analysis, as were the
medications previously reported to influence uric acid lev-
els[12]. However, measurements of the urinary glucose
were not included, since the semi-quantitative scale
tended to have a non-linear effect on the change in uric
acid concentration. Unless otherwise mentioned, test for
relevant interactions were found to be non-significant
(p > 0.05).
Data available by September 2006 were used in all analy-
ses. All calculations were made using SAS®, version 9.1
(SAS institute, Cary, North Carolina). The level of statisti-
cal significance was set at a p-value < 0.05.
Results
The study included 10729 patients, of whom 2584 (24%)
were classified as having only DM, 1748 patients (16%) as
having only CVD, and 6397 patients (60%) as having
both DM and CVD. The main characteristics of the differ-
ent groups are shown in Table 1.
At screening, uric acid concentrations were significantly
higher among patients with a history of CVD, compared
to patients with only DM (CVD group, compared to DM
group: p < 0.0001 and CVD+DM, compared to DM group:
p < 0.0001). Patients using diuretics had significantly
higher uric acid concentrations, compared to patients not
using diuretics (mean ± standard deviation [SD]: 388 ±
101  μmol/L, and 345 ± 84 μmol/L, respectively, p <
0.0001). Analyses stratified by use of diuretics also found
CVD patients had higher uric acid concentrations, com-
Table 1: Screening characteristics
DM only CVD only CVD+DM
n = 2584 n = 1748 n = 6397
Age (years) 62 (± 6) 64 (± 6) 64 (± 6)
Male gender (%) 38% 66% 64%
BMI (kg/m2) 35.9 (± 4.8) 33.4 (± 4.1) 34.0 (± 4.4)
Weight (kg) 97.4 (± 16.1) 95.0 (± 14.8) 95.8 (± 15.4)
Waist circumference, men (cm) 117 (± 12) 112 (± 10) 114 (± 10)
Waist circumference, women (cm) 111 (± 12) 104 (± 11) 109 (± 11)
Systolic blood pressure (mmHg) 141 (± 12) 136 (± 13) 138 (± 13)
Diastolic blood pressure (mmHg) 78 (± 8) 78 (± 8) 77 (± 9)
Pulse (bpm) 75 (± 10) 68 (± 10) 71 (± 10)
Creatinine clearance (mL/min/1.73 m2) 76 [48;105] 72 [47;99] 71 [41;103]
Uric acid concentration (μmol/L) 342 (± 87) 369 (± 86) 374 (± 98)
Glucose concentration (mmol/L) 9.0 (± 3.1) 6.0 (± 1.0) 8.9 (± 3.2)
HDL cholesterol (mmol/L) 1.3 (± 0.3) 1.2 (± 0.3) 1.2 (± 0.3)
LDL cholesterol (mmol/L) 3.1 (± 0.9) 3.0 (± 0.9) 3.0 (± 1.0)
Triglycerides (mmol/L) 2.2 (± 1.5) 2.0 (± 1.1) 2.4 (± 1.4)
History of dyslipidaemia (%) 71% 76% 86%
History of stroke (%) 0% 9% 12%
Peripherial artery disease (%) 0% 8% 16%
Use of alcohol (%) 51% 63% 54%
Current smokers (%) 11% 10% 9%
Coronary artery disease (%) 4% 87% 83%
CHF (%) 2% 9% 11%
Use of diuretics (%) 45% 37% 51%
Use of Insulin (%) 2 6 %0 . 5 %3 2 %
Use of statins (%) 42% 73% 73%
Use of ACE-inhibitors (%) 73% 64% 82%
Use of Ca2+-blockers (%) 32% 33% 40%
Use of fibrates (%) 10% 6% 10%
Urinary dip stick for glucose:
Negative (%) 81% 99% 79%
Trace (%) 6% 0.4% 6%
1+ (%) 4% 0.2% 5%
2+ (%) 3% 0.1% 3%
3+ (%) 6% 0.4% 6%
Continuous variables are presented as means (± standard deviation) and discrete variables as percentages (%). Creatinine clearance is presented as 
median [5th 95th percentiles] due to widely distributed values. Blood samples were obtained during screening visit, as were medical histories. 
Weight, BMI, waist circumference, pulse and blood pressure are values from the first day of sibutramine administration.Nutrition & Metabolism 2009, 6:42 http://www.nutritionandmetabolism.com/content/6/1/42
Page 4 of 9
(page number not for citation purposes)
pared to non-CVD patients irrespective of diuretic use
(data not shown).
Over the first four weeks of sibutramine-based therapy,
mean uric acid concentration decreased significantly in all
three groups (Figure 1). Patients with diabetes had signif-
icantly smaller reductions in uric acid (DM only group,
compared to CVD only group: p < 0.0001 and CVD+DM,
compared to CVD only group: p < 0.0001). Mean weight
loss was 2.2% (± SD 1.8), 2.1% (± 1.8) and 2.4% (± 1.9)
in the DM only, CVD+DM, and CVD only group, respec-
tively. Multiple factors were significantly associated with a
four week change in uric acid concentration, as shown in
the left column of Table 2. As indicated with (*) or (†) in
Table 2, many of the factors were found to affect the
change in uric acid levels differently in patients with and
without diabetes.
Diabetes status and the influence of weight loss and 
changes in fasting glucose on uric acid concentration
Figure 2 and 3 illustrate the influence of changes in weight
and fasting serum glucose on uric acid levels in patients
with and without diabetes, respectively.
In patients with diabetes, increasing weight loss with sib-
utramine and lifestyle changes was associated with
smaller reductions in uric acid. Adjusted for multiple var-
iables, each 1% reduction in weight was associated with a
2.9 (± standard error [SE] 0.4, p < 0.0001) μmol/L smaller
fall in uric acid concentration. In patients without diabe-
tes, weight loss had no detectable impact on the uric acid
levels: a 1% reduction in weight was associated with a 0.6
(± 0.7, p = 0.4) μmol/L increase in uric acid concentration.
The difference in impact of weight loss between patients
with and without diabetes was statistically significant
(p for difference in multivariable analysis = 0.0003).
Decreasing levels of fasting serum glucose were associated
with different changes in the uric acid levels in patients
with and without diabetes (p for interaction in multivari-
able analysis <0.0001). Adjusted for multiple variables,
each 1 mmol/L decrease in fasting serum glucose was
associated with a 1.7 (± 0.3, p < 0.0001) μmol/L smaller
fall in uric acid concentration in patients with diabetes.
Conversely, each 1 mmol/L decrease in fasting serum glu-
cose was associated with a 3.7 (± 1.5, p = 0.01) μmol/L
larger fall in uric acid concentration in patients without
diabetes.
Urinary glucose and its influence on serum uric acid 
concentration
At the screening visit almost all patients without diabetes
(99%) and approximately 80% of the patients with diabe-
tes had a negative dip stick for urinary glucose. However,
those patients showing a change in urinary glucose, meas-
ured by dip stick, were found to significantly alter their
uric acid levels, as illustrated for all patients with diabetes
in Figure 4. When glycosuria increased during the first 4
weeks of treatment with sibutramine and lifestyle
changes, uric acid levels tended to fall; however, levels
actually increased progressively in those with less
glycosuria.
Discussion
The once-daily treatment with sibutramine plus diet and
exercise for four weeks induced significant mean reduc-
tions in uric acid concentrations overall, and patients
without diabetes had greater reductions than those
patients with diabetes. However, the significant fall in uric
acid in the subgroup of patients gaining/maintaining their
initial weight suggests a specific uric acid lowering effect
of sibutramine and the results from some previous pla-
cebo controlled studies of sibutramine agree with this
hypothesis with greater falls in uric acid for the same
weight loss in sibutramine compared with placebo treated
patients[13-15].
The present study found the response of weight loss and
falling serum glucose levels on uric acid levels to be
strongly modified by diabetes. In patients without diabe-
tes weight loss had no detectable influence on uric acid
concentrations and decreasing serum glucose concentra-
tions were associated with decreasing uric acid levels. In
patients with diabetes weight loss were found to have a
paradoxical effect on the fall in uric acid concentrations -
those with no weight loss and limited changes in blood
Four week change in uric acid concentration, stratified for  the presence of only diabetes mellitus (DM), only cardiovas- cular disease (CVD) or both (p-value for changes <0.0001 in  respectively group) Figure 1
Four week change in uric acid concentration, strati-
fied for the presence of only diabetes mellitus (DM), 
only cardiovascular disease (CVD) or both (p-value 
for changes <0.0001 in respectively group). Error bars 
illustrate 95% confidence interval.Nutrition & Metabolism 2009, 6:42 http://www.nutritionandmetabolism.com/content/6/1/42
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glucose had the greatest uric acid reductions whereas
those with maximum weight loss had negligible falls.
Physiological mechanisms involved in uric acid metabolism
Renal elimination is the single most important factor reg-
ulating blood uric acid levels[16]. Uric acid is freely fil-
tered through the renal glomerulus and uric acid
concentration in blood is primary regulated by the degree
of uric acid reuptake. Several transporters situated in the
proximal tubule participate in uric acid reabsorption, and
normally only 10% of the filtered load is excreted[17].
The most important uric acid transporter in the apical
membrane has been considered to be the URAT1 trans-
porter, which is thought to act in combination with two
sodium-coupled monocarboxylate transporters (SMCT1
and SMCT2), as a "urate transportsome"[17]. This com-
plex is influenced by a wide range of factors, such as inor-
ganic and organic anions and several uricosuric drugs[17].
The uric acid is thought to then leave the tubule cell via
the recently described SLC2A9 transporter, previously des-
ignated as the Glut9 transporter[18,19]. Several drugs
have recently been described as inhibiting the SLC2A9
Table 2: Variables with a significant effect on the four week change in uric acid. Results from multivariable regression analysis
All patients Diabetes No diabetes
Estimated influence on uric 
acid concentration ( mol/L):
p-value: Estimated influence on uric 
acid concentration ( mol/L):
p-value: Estimated influence on uric 
acid concentration ( mol/L):
p-value:
Change in glucose 
concentration (for 1 mmol/L 
decrease) *
1.6 (± 0.3) <0.0001 1.7 (± 0.3) <0.0001 -3.8 (± 1.5) 0.01
Weight loss, for 1% decrease 
*
2.5 (± 0.3) <0.0001 2.9 (± 0.4) <0.0001 0.6 (± 0.7) 0.4
LDL change (for 1 mmol/L 
decrease) †
-7.4 (± 0.9) <0.0001 -6.4 (± 1.1) <0.0001 -11.7 (± 2.0) <0.0001
Triglyceride change 
(for 1 mmol/L decrease)
-6.3 (± 1.1) <0.0001 -6.0 (± 1.2) <0.0001 -7.4 (± 2.6) 0.004
Change in systolic blood 
pressure 
(for 1 mmHg decrease)
0.3 (± 0.07) <0.0001 0.3 (± 0.08) 0.0002 0.1 (± 0.1) 0.5
Use of fibrates -14.7 (± 2.1) <0.0001 -15.3 (± 2.2) <0.0001 -8.9 (± 5.7) 0.1
Triglyceride concentration at 
baseline 
(for 1 mmol/L increment)
5.5 (± 0.9) <0.0001 5.8 (± 1.0) <0.0001 3.6 (± 2.2) 0.1
Use of diuretics 11.9 (± 1.2) <0.0001 12.1 (± 1.4) <0.0001 10.0 (± 2.9) 0.0007
Uric acid concentration at 
baseline (for 1 μmol/L 
increment)
-0.2 (± 0.01) <0.0001 -0.3 (± 0.007) <0.0001 -0.2 (± 0.02) <0.0001
Creatinine clearance at 
baseline (for 1 mL/min/1.73 
m2 increment)
-0.08 (± 0.02) <0.0001 -0.07 (± 0.02) <0.0001 -0.2 (± 0.06) <0.0001
Change in creatinine 
clearance (for 1 mL/min/1.73 
m2 increase)
0.1 (± 0.01) <0.0001 0.1 (± 0.02) <0.0001 0.2 (± 0.05) <0.0001
Male gender 10.2 (± 1.4) <0.0001 10.2 (± 1.6) <0.0001 11.1 (± 3.5) 0.001
Waist circumference at 
baseline (for 1 cm increment)
0.2 (± 0.07) 0.001 0.2 (± 0.08) 0.007 0.2 (± 0.1) 0.1
BMI at screening (for 1 kg/m2 
increment)
0.5 (± 0.2) 0.01 0.5 (± 0.2) 0.02 0.5 (± 0.4) 0.3
HDL change (for 1 mmol/L 
decrease) *
5.7 (± 4.0) 0.2 10.0 (± 4.5) 0.03 -10.8 (± 8.3) 0.2
LDL at screening 
(for 1 mmol/L decrement)
0.3 (± 0.7) 0.6 0.8 (± 0.8) 0.3 -3.6 (± 1.6) 0.02
Type 2 diabetes mellitus 5.9 (± 1.7) 0.0004 - - -
The stratum "diabetes" includes the patients in the DM only group and the CVD+DM group. "No diabetes" includes the patients in CVD only 
group. Only variables at a significance level of ≤ 0.05 in overall group or in any of the two groups are presented in table. Analysis was also adjusted 
for screening features (age, smoking status, a diagnosis of heart failure, systolic and diastolic blood pressure, pulse, glucose concentration at 
baseline, and HDL cholesterol at baseline), medication use (insulin, aspirin, ACE-inhibitors, calcium channel blockers, statins) and dynamic variables 
(changes in diastolic blood pressure and pulse). SE = standard error. (*) and (†) indicate a p-value ≤ 0.01 and p-value ≤ 0.05 respectively for 
differences in the influence on uric acid between patients with and without diabetes.Nutrition & Metabolism 2009, 6:42 http://www.nutritionandmetabolism.com/content/6/1/42
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Mean change in uric acid concentration, according to four week weight change (left) and four week mean change in fasting  serum glucose (FSG, right) in patients with diabetes Figure 2
Mean change in uric acid concentration, according to four week weight change (left) and four week mean 
change in fasting serum glucose (FSG, right) in patients with diabetes. "Numbers" refers to the numbers of patients 
with available values on the uric acid change in the respective group. The mean uric acid concentration change was found to 
differ in both the groups of weight change and the groups of FSG change (p < 0.0001 in both analyses). Error bars illustrate 95% 
confidence interval.
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) Diabetes group: Influence of a change in weight (left) and a change in fasting serum glucose (right) on uric acid concentration change:
Weight change Gained Lost <1% Lost <2% Lost <3% Lost <4% Lost >4%
Numbers 882 1208 2024 1818 1173 1075
Mean change in FSG (mmol/L) -0.1 (±3.0) -0.3 (±2.6) -0.3 (±2.5) -0.7 (±2.5) -0.8 (±2.4) -1.0 (±2.5)
Change in FSG (mmol/L) >2 >1;2 0;1 <0; -1 <-1; -2 < -2
Numbers 769 688 2037 2057 1077 1614
Mean weight loss (%) 1.6 (±1.6) 1.8 (±1.6) 2.0 (±1.7) 2.2 (±1.7) 2.4 (±1.8) 2.3 (±1.9)
Mean change in uric acid concentration, according to four week weight change (left) and four week mean change in fasting  serum glucose (FSG, right) in patients without diabetes Figure 3
Mean change in uric acid concentration, according to four week weight change (left) and four week mean 
change in fasting serum glucose (FSG, right) in patients without diabetes. "Numbers" refers to the numbers of 
patients with available values on the uric acid change in the respective group. No difference was found in mean uric acid con-
centration change between the weight change groups (p = 0.3). The mean uric acid concentration change was found to differ 
over the groups of FSG change (p = 0.0004). Error bars illustrate the 95% confidence interval.
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Non diabetes group: Influence of weight change (left) and a change in fasting serum glucose (right) on uric acid concentration change:
Weight change Gained Lost <1% Lost <2% Lost <3% Lost <4% Lost >4%
Numbers 133 194 371 373 265 269
Mean change in FSG 
(mmol/L)
-0.005
(±0.9)
0.03
(±0.8)
0.03
(±0.7)
0.04
(±1.0)
0.04
(±1.1)
-0.1
(±0.9)
Change in FSG (mmol/L) >2 >1;2 0;1 <0; -1 <-1; -2 < -2
Numbers 25 85 652 752 76 25
Mean weight loss (%) 2.4 (±1.8) 2.1 (±2.0) 2.3 (±1.8) 2.5 (±1.9) 2.6 (±2.3) 2.8 (±1.8)Nutrition & Metabolism 2009, 6:42 http://www.nutritionandmetabolism.com/content/6/1/42
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transporter and thereby increasing uric acid excretion and
decreasing uric acid blood levels[18]. Potentially, sibu-
tramine may be simulating these other drugs.
SLC2A9, uric acid and glucose
The SLC2A9 transporter seems to be comprised of two
splice variants: the Glut9 transporter, which is situated in
the basolateral membrane, and the Glut9ΔN, which is sit-
uated in the apical membrane[20]. To our knowledge,
two in vitro studies have investigated the characteristics of
the SLC2A9 transporter[18,19]. One of the two studies
found uric acid transport to be modestly accelerated by
extra-cellular glucose, with the mechanism being classical
exchange trans-stimulation between uric acid and glucose
or fructose[19]. Importantly, this study seems to investi-
gate both splice variants at the same time[19]. The other
study focuses on the basolateral variant and found no
stimulation of uric acid transport rate by extracellular glu-
cose[17]. Hence, it seems that the exchange between uric
acid and glucose is limited to the apical situated uric acid
transporter.
Differential effects of decreasing serum glucose levels on 
uric acid concentrations in diabetes
The different serum uric acid responses to decreasing lev-
els of fasting glucose in patients with and without diabetes
have been previously described with Chinese adults with-
out diabetes also showing higher uric acid levels with
higher fasting blood glucose whereas the opposite effect
was seen in those with newly diagnosed diabetes[21].
The present study demonstrated that a decrease in serum
glucose concentration was associated with a decrease in
uric acid levels in patients without diabetes (Figure 3).
Given that this patient group had cardiovascular disease
and a relatively high fasting glucose (6.0 [±1.0] mmol/L)
it is likely that these patients were insulin resistant with
hyperinsulinaemia. As they lost weight however, serum
insulin levels may have improved. Since insulin concen-
trations are inversely related to the urinary uric acid clear-
ance[22,23], and infusing insulin has been shown to
enhance coupled sodium and uric acid reabsorption[24],
decreasing insulin levels might have limited the reabsorp-
tion of uric acid thereby helping to reduce blood uric acid
levels. Patients with diabetes could be expected to experi-
ence a similar trend. However, patients with diabetes also
display higher fasting glucose levels and are recognized to
have much larger post-prandial blood glucose surges with
greater glucose loading of the kidneys. Figure 4 presents
the most direct evidence of the interactions between the
renal handling of glucose and the renal mechanisms con-
trolling blood uric acid levels. Thus, when there was little
change in fasting glucose there was minimum change in
the renal excretion of glucose and only about 10 μmol/L
lower blood uric acid levels during the weight loss period
whereas a deterioration in their diabetes control with an
increase in fasting glucose (with probably higher insulin
levels) was linked to a greater spillover of urinary glucose
and the most marked fall in blood uric acid levels seen in
the whole population group. This effect is the opposite of
that expected from changes in insulin unless the insulin-
mediated mechanism for uric acid reabsorption also dis-
plays progressive impaired effectiveness as well as in nor-
mal body glucose disposal. Those who reduced both their
fasting and urinary glucose would be expected to lower
their plasma insulin levels which would reduce renal uric
acid reabsorption and lower blood uric acid concentra-
tions. Yet the blood uric acid levels responded in the
opposite direction by increasing markedly in this group
and the range of urinary glucose-related responses in
blood uric acid changes displayed almost a 100 μmol/L
range. The recognized properties of the apical situated
SLC2A9 transporter, i.e. exchanging intracellular uric acid
for tubular glucose, seems therefore to be the explanation
for the different responses: the greater load of glucose to
the kidney in patients with diabetes is likely to facilitate
uric acid excretion thereby markedly reducing blood uric
acid levels as the diabetes state deteriorates.
The paradoxical relationship found between weight loss
and uric acid levels in patients with diabetes is assumed to
be secondary to the previously discussed differences in
Mean change in uric acid concentration for patients with dia- betes, according to four week change in urinary glucose, esti- mated by dip stick Figure 4
Mean change in uric acid concentration for patients 
with diabetes, according to four week change in uri-
nary glucose, estimated by dip stick. The dip stick scale 
ranged between "negative", "trace", "1+", "2+" and "3+" for 
glucose content. FSG = fasting serum glucose. Error bars 
illustrate 95% confidence interval. Variables in table are pre-
sented as means (± standard deviation). Analysis for patients 
without diabetes was not performed, since 99% of the 
patients had a negative dip stick at screening, and 99% of the 
patients were found to have no change in glucose dip stick.
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Urinary glucose change (units) -4 -3 -2 -1 0 +1 +2 +3 +4
Numbers 170 170 280 446 6097 333 153 74 41
Mean weight loss (%) 2.1
(±1.8)
2.4
(±1.9)
2.0
(±1.7)
2.2
(±2.0)
2.2
(±1.8)
1.8
(±1.6)
1.6
(±1.4)
1.5
(±1.4)
1.3
(±1.7)
Mean change in FSG 
(mmol/L)
-5.8
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-1.9
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-0.3
(±1.9)
1.1
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response of uric acid to falling serum glucose levels. How-
ever, it cannot be excluded that some of the inverse rela-
tionship between uric acid decrease and weight loss also
potentially could be explained by factors like increased
cell catabolism, as uric acid has previously been shown to
increase during fasting[25].
Other factors influencing uric acid concentrations
The relationship of uric acid levels to a change in HDL and
LDL cholesterol seems of minor significance but the use of
fibrates did seem to amplify the falls in serum uric acid.
Multivariable analysis suggested that fibrates reduce by
about a further 10 μmol/L the fall in uric acid observed
over the four week period. Previous studies have shown a
uric acid lowering effect of fenofibrate, with suggested
mechanisms linked to increased urinary uric acid excre-
tion[26-28], but the transporters involved are currently
unclear. The converse effect applies to diuretics with
increases in blood uric acid levels but hydrochlorthiazide
has been found not to affect the basolateral membrane
variant of SLC2A9 uric acid transport in vitro[18]. It is
possible that induced uric acid reabsorption by diuretics
counteracted the suggested sibutramine effect in some
way. None of the other drugs included in the analysis
(aspirin, ACE-inhibitors, calcium channel blockers or stat-
ins) was shown to have an influence on the change in uric
acid concentrations.
Limitations of the study
The present study was based on data obtained during four
weeks of treatment with sibutramine, diet and exercise.
Because fat masses and body fluids may have changed
dynamically during this period, any observed relationship
between uric acid, sibutramine, serum/renal glucose, and
diabetes should be regarded as hypothesis-generating
only. The lead-in period was non-randomized, single-
blind and had no control group; therefore a direct uric
acid lowering effect of sibutramine could not be isolated
in this study, but has been demonstrated in previous pla-
cebo-controlled trials[8].
There is also a possibility that the results were affected by
regression towards the mean or other factors. In particu-
lar, the higher screening values of uric acid among
patients with CVD compared to that in patients without
CVD could potentially account for some of the difference
found in uric acid decrease between patients with and
without diabetes. However, the fact that the group with
CVD only and the group with DM+CVD had comparable
screening values of uric acid but differences in decrement
over the study period suggests that other factors were of
importance. In addition, baseline values of uric acid were
included in multivariable regression analysis.
Furthermore, measurements of insulin concentrations
were lacking and their measurement would have helped
in the interpretation of the data. On the other hand,
serum insulin levels in patients with diabetes can be vari-
able depending on the length of time with the disease, the
type of therapy and the presence of differing degrees of
insulin resistance. Also glycated haemoglobin could have
been helpful in the interpretation of data; however, due to
the design of the study and run-in period, there was not
data available to permit meaningful analysis.
Anti-gout medication was not recorded in the study, but
since nearly all uric acid values were within the normal
range, the influence of such medication can be assumed to
be minor. In addition genetic variation of the renal
SCL2A9 transporter for uric acid transporters is now rec-
ognised to account for some of the variation in uric acid
concentrations[19]. However, no such information on the
genetic profiles of the SCOUT population is as yet
available.
Conclusion
A four week daily intake of sibutramine and life style
changes was associated with a significant reduction in
mean uric acid levels but the renal glucose load in patients
with diabetes tended to counteract any selective uricosuric
effect of sibutramine. The uric acid reduction during this
short period of weight management was more pro-
nounced in patients without diabetes.
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